Co-Diagnostics Enters and Terminates Material Agreements
Ticker: CODX · Form: 8-K · Filed: Oct 20, 2025 · CIK: 1692415
| Field | Detail |
|---|---|
| Company | Co-Diagnostics, Inc. (CODX) |
| Form Type | 8-K |
| Filed Date | Oct 20, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $10,000,000, $4,086,645 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, termination
Related Tickers: CDXC
TL;DR
CDXC entered and terminated a material agreement on 9/30/25. Big moves happening.
AI Summary
Co-Diagnostics, Inc. reported on September 30, 2025, that it entered into a material definitive agreement and also terminated a material definitive agreement. The company, incorporated in Utah with its principal executive offices in Salt Lake City, filed this Form 8-K to disclose these events.
Why It Matters
This filing indicates significant changes in Co-Diagnostics' contractual relationships, which could impact its operations, partnerships, and financial standing.
Risk Assessment
Risk Level: medium — The entry into and termination of material agreements can signal significant strategic shifts or potential disputes, warranting closer examination.
Key Players & Entities
- Co-Diagnostics, Inc. (company) — Registrant
- September 30, 2025 (date) — Date of earliest event reported
- Utah (location) — State of incorporation
- Salt Lake City (location) — Principal executive offices
FAQ
What was the nature of the material definitive agreement entered into by Co-Diagnostics?
The filing does not specify the nature of the material definitive agreement entered into.
What were the reasons for the termination of the material definitive agreement?
The filing does not provide details regarding the reasons for the termination of the material definitive agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 30, 2025.
Where are Co-Diagnostics, Inc.'s principal executive offices located?
Co-Diagnostics, Inc.'s principal executive offices are located at 2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109.
What is the Standard Industrial Classification code for Co-Diagnostics, Inc.?
The Standard Industrial Classification code for Co-Diagnostics, Inc. is 3841 (Surgical & Medical Instruments & Apparatus).
Filing Stats: 1,217 words · 5 min read · ~4 pages · Grade level 13.1 · Accepted 2025-10-20 09:42:25
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CODX The Nasdaq Capital M
- $10,000,000 — g an aggregate offering amount of up to $10,000,000 (the "Shares") during the term of the A
- $4,086,645 — prospectus supplement registering up to $4,086,645 of Shares relating to the ATM Offering
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex5-1.htm (EX-5.1) — 13KB
- ex10-1.htm (EX-10.1) — 216KB
- ex5-1_001.jpg (GRAPHIC) — 8KB
- 0001493152-25-018591.txt ( ) — 504KB
- codx-20250930.xsd (EX-101.SCH) — 3KB
- codx-20250930_lab.xml (EX-101.LAB) — 33KB
- codx-20250930_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
02. Termination of a Material Definitive Agreement
Item 1.02. Termination of a Material Definitive Agreement Effective September 30, 2025, the Company terminated the Amended and Restated Equity Distribution Agreement dated April 25, 2025, by and between the Company, Piper Sandler & Co., and Clear Street LLC, which provided for sales of the Company's common stock in an at-the-market offering. Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 5.1 Opinion of Dorsey & Whitney LLP 10.1 Equity Distribution Agreement between Co-Diagnostics, Inc. and Maxim Group LLC, dated October 20, 2025 23.1 Consent of Dorsey & Whitney LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CO-DIAGNOSTICS, INC. Date: October 20, 2025 By: /s/ Brian Brown Name: Brian Brown Title: Chief Financial Officer (Principal Financial and Accounting Officer)